Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Search By Keywords
Example: Diabetes, Cardiology, John Smith
Browse by Disease or Condition
Recently Added/Updated Trials
Plasma Donor Registry for Patients Recovered from Confirmed COVID-19Penn Medicine is seeking plasma donation from eligible healthy volunteers for a research study. Interested volunteers must have recovered from a COVID-19 positive diagnosis (made ...Read more
Changing the Trajectory of Mild Cognitive Impairment with CPAP Treatment of Obstructive Sleep Apnea (Memories 2)Are you having any trouble with your memory or sleep?This research study will explore whether treating sleep apnea can improve memory. Compensation is up ...Read more
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID 19 in Hospitalized AdultsRead moreThis study is for patients in the hospital being treated for COVID-19There are no approved medications to treat COVID-19 because it is a new ...
Multimodal imaging outcome measures for ALS (Image ALS)This research study is being done to learn more about changes over time in Positron Emission Tomography/Computed Tomography (PET/CT) imaging in people with ...Read more
Randomized Controlled Trial Examining the Effects of Meal Timing Among Obese Individuals!--[if>![endif]-->!--[if>![endif]-->!--[if>Read more
SPYAL HTN-ON Med for Hypertension
You are being asked to take part in a clinical research study because your blood pressure (BP) is not adequately controlled with medications. Purpose of ... Read more
A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS)
Primary FSGS is a progressive disease that causes the kidneys to scar, to leak protein into the urine and may lead to kidney failure. This ... Read more
An Open-Label Phase 2 Proof or Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471
This is an open-label study of 12 months of dosing with ACH-0144471. The study will enroll patients with biopsy-confirmed C3G or IC-MPGN who meet eligibility ... Read more